Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rxo (RXO) EBITDA (2021 - 2025)

Rxo (RXO) has disclosed EBITDA for 5 consecutive years, with -$42.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 75.0% year-over-year to -$42.0 million, compared with a TTM value of -$79.0 million through Dec 2025, down 41.07%, and an annual FY2025 reading of -$79.0 million, down 41.07% over the prior year.
  • EBITDA was -$42.0 million for Q4 2025 at Rxo, down from -$7.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $58.0 million in Q2 2022 and bottomed at -$42.0 million in Q4 2025.
  • Average EBITDA over 5 years is $5.5 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw EBITDA surged 1500.0% in 2023, then tumbled 433.33% in 2024.
  • Year by year, EBITDA stood at $55.0 million in 2021, then tumbled by 101.82% to -$1.0 million in 2022, then soared by 1500.0% to $14.0 million in 2023, then plummeted by 271.43% to -$24.0 million in 2024, then crashed by 75.0% to -$42.0 million in 2025.
  • Business Quant data shows EBITDA for RXO at -$42.0 million in Q4 2025, -$7.0 million in Q3 2025, and -$30.0 million in Q1 2025.